Form 4 for CCCC C4 Therapeutics, Inc.
Accepted 2024-04-10 00:00:00 ET · period of report 2024-02-14 · accession 0001662579-24-000040 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-04-10 | 2024-02-14 | CCCC | Mossler Mark | CAO | A - Grant | $0.00 | +18.3K | 19.8K | +1,219% | $0 |
| D | 2024-04-10 | 2024-02-14 | CCCC | Mossler Mark | CAO | A - Grant | $0.00 | +27.4K | 27.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-14 | A | A | 18,290 | $0.00 | 19,790 | D | — | — | (F2) Includes 1,500 shares of Common Stock that were inadvertently omitted from the Form 3 filed by the Reporting Person on September 19, 2023. |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-02-14 | A | A | 27,430 | $0.00 | 27,430 | D | $7.31 · — to 2034-02-13 | 27,430 Common Stock | (F3) The shares underlying this option shall vest and become exercisable in sixteen equal quarterly installments following the grant date, with the first installment vesting on May 14, 2024. |